Meningococcal Vaccines Market | USD 6.96 Billion by 2034
The meningococcal vaccines market size was exhibited at USD 3.85 billion in 2024 and is projected to hit around USD 6.96 billion by 2034, growing at a CAGR of 6.1% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 4.08 Billion |
| Market Size by 2034 | USD 6.96 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 6.1% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Type, Brand, Serotype, Age group, Sales Channels, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America, Europe, Asia Pacific, Latin America, MEA |
| Key Companies Profiled | Pfizer Inc.; Sanofi; Serum Institute of India Ltd.; GSK plc; Merck & Co., Inc.; Walvax Biotechnology Co., Ltd. |
The increasing prevalence of meningitis is one of the major factors expected to drive the market. According to the Centers for Disease Control and Prevention (CDC), around 1.2 million cases of bacterial meningitis are projected to occur globally every year. Moreover, increasing immunization programs, growing awareness about the disease, and increasing R&D activities pertaining to meningococcal vaccines are expected to fuel market growth during the forecast period.
The overall market experienced a decline in 2020 owing to the COVID-19 pandemic. The net sales of Menactra, Menveo, Nimenrix, Trumenba, and Bexsero were negatively impacted in 2020. However, the market is expected to grow at a positive Y-o-Y growth rate in 2024 due to increasing initiatives by government and regulatory authorities to combat the rising prevalence of meningitis. For instance, in May 2019, the Ministry of Health of Ireland approved MenACWY vaccine to be provided to thousands of teenagers in Ireland, due to the rising prevalence of meningitis in 2018.
Various campaigns and awareness programs are being organized by government & non-government organizations, such as the National Meningitis Association (NMA), Meningitis Research Foundation of Canada, Meningitis B Action Project, and others. These organizations help in promoting continuous research and new approaches involved in disease prevention. Hence, these factors are anticipated to fuel the meningococcal vaccine market growth in the coming years.
The presence of non-profit organizations providing support for research projects, training to healthcare professionals, and offering information & help to patients is anticipated to accelerate market growth. For instance, in August 2021, DoSomething.Org and National Foundation for Infectious Diseases (NFID) introduced the "Complete What's Missing Program". The program's goal is to educate young people about the importance of Meningococcal Disease Prevention.
The presence of phase III vaccines in the pipeline which are expected to be commercialized over the forecast period is anticipated to fuel the market growth. For instance, in June 2020, Pfizer, Inc. initiated phase III clinical trials of PF-06886992, a pentavalent meningococcal vaccine candidate (MenABCWY) to assess & compare the safety, immunogenicity, and tolerability with licensed meningococcal vaccines in adolescents and young adults. Moreover, Menactra, a conjugate vaccine manufactured by Serum Institute of India Pvt. Ltd. is currently in phase III clinical trial.
Based on type, the market is segmented into bivalent, quadrivalent, and others. Quadrivalent vaccines accounted for the largest revenue share of 51.1% in 2024 owing to widely used brands such as Menactra, Menveo, and Nimenrix. Moreover, approval of new vaccines to protect people against meningococcal vaccines is anticipated to fuel the growth of this market. For instance, in April 2021, Sanofi received U.S. FDA approval for MenQuadfi. It is a quadrivalent meningococcal (Groups A, C, Y, W) conjugate vaccine for the prevention of invasive meningococcal disease in people 2 years & older.
Bivalent vaccines held the second largest market share owing to the high adoption rate coupled with the low cost and inclusion of these vaccines in various programs undertaken by governments of different countries. For instance, in China, MenA and MenAC are conjugate vaccines included in the multistage meningococcal vaccination program for children aged 6 to 18 months for MenA vaccine and aged 3 to 6 for MenAC vaccine. Apart from this, others segment consists of monovalent, trivalent, and pentavalent vaccines.
Based on brand segment, Bexsero accounted for the largest revenue share of 32.6% in 2024 owing to fewer doctor visits, lower costs and reduced doses. Bexsero is licensed in more than 40 countries, such as New Zealand, Argentina, Chile, Australia, Israel, Uruguay, Turkey, and Europe, and is intended for individuals aged 2 months & above. Moreover, the high adoption rate of the vaccine to protect against meningococcal infection caused by serotype B has increased the segment share. Additionally from March 2023, Bexsero will be funded to immune children up to 12 months of age, under the childhood immunization programme and for people with 13 to 25 years of age.
Trumenba is expected to grow at the fastest rate over the forecast period. The growth of the vaccine is mainly driven by the increasing awareness of the disease and increasing marketing approval across the globe. For instance, in May 2017, the European Commission approved Pfizer, Inc.’s Trumenba to protect individuals aged 10 & above from IMD caused by MenB. Moreover, In July 2017, the U.K. approved Trumenba for individuals aged 10 and above. Thus, the segment is anticipated to grow at the highest rate.
Serotype B segment dominated the global market with a revenue share of 36.3% in 2024. This can be attributed to the presence of strong vaccines such as Trumenba & Bexsero available in the market and the increasing disease burden of MenB worldwide. In North America and the European region, Serotype B is the predominant agent causing meningococcal disease. It causes around half of the total reported cases of meningococcal disease in these regions. Moreover, increasing research activities to develop pentavalent vaccines including protection against serotype B is further expected to increase the market growth over the forecast period.
However, the serotype C segment is anticipated to experience the fastest growth over the forecast period. The growth of the segment can be attributed to the high effectiveness of vaccines and the increasing inclusion of vaccines in vaccination programs of countries. For instance, countries such as U.K., Australia, Belgium, France, Germany, Iceland, Ireland, the Netherlands, and others have included serogroup C conjugate vaccine in their National Immunization Program.
The children & adults segment held the largest market share of 79.0% in 2024 owing to initiatives undertaken by healthcare organizations to vaccinate the adult population and ongoing clinical trials to develop novel vaccines for teenagers. For instance, in February 2020, ACIP released recommended Immunization Schedule for adults, with changes to the administration of the meningococcal B conjugate vaccines.
The infants segment is expected to be the fastest-growing segment over the forecast period owing to the rising prevalence of meningitis. For instance, according to European Centre for Disease Prevention and Control (ECDC), in 2017, IMD incidence was observed to be the highest in infants. In Europe, the prevalence was found to be 8.2 confirmed cases per 100,000 children of age below 1 year. In addition, growing research on available vaccines to determine their impact on preventing the target disease is anticipated to boost the market growth.
Based on sales channel, the public sales channel segment held the largest market share of 69.4% in 2024 and is anticipated to maintain its dominance throughout the forecast period. A large share of the segment can be attributed to the inclusion of major meningococcal vaccine brands, such as Trumenba, Bexsero, Menactra, Nimenrix, Menveo, and others in immunization programs in a major market for vaccination against meningococcal infections. For instance, in July 2020, the government of New South Wales changed the immunization schedule, and the government is funding Bexsero for Aboriginal children & some at-risk people and Nimenrix for people at high risk of infection.
The private sales channel is mainly driven by increasing demand for meningococcal vaccines in developing countries. Moreover, increasing disposable income, increasing outbound traveling from work, study, pilgrims for Mecca and Umrah, and increasing awareness is driving the demand for vaccination against meningococcal vaccines through private sales channels.
North America dominated the overall market in terms of revenue in 2024 with a share of 57.0%, followed by Europe. Favorable recommendations & support from governments and high R&D investments are some factors driving the North America market. Moreover, a well-developed healthcare structure and an increase in awareness campaigns in the region are anticipated to propel market growth. Market players are also actively involved in an awareness campaign to increase the adoption of the meningococcal vaccine in the region. For instance, in August 2021, GSK plc. Launched ASK2BSure campaign for encouraging parents to consult the doctors for meningitis B vaccination of their children.
The Asia Pacific market is expected to grow at a significant rate during the forecast period. The increasing pediatric population and increasing initiatives by the government to combat the rising prevalence of the disease are contributing to the growth of the meningococcal vaccines in this region. Moreover, non-profit organizations present in the region provide information and increase awareness among people and healthcare professionals. Hence, expected to increase the adoption of vaccination against meningococcal infections.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the meningococcal vaccines market
Type
Brand
Age Group
Serotype
Sales Channel
Regional
Chapter 1 Meningococcal Vaccines Market: Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Meningococcal Vaccines Market: Executive Summary
2.1 Market Summary
Chapter 3 Meningococcal Vaccines Market: Variables, Trends, And Scope
3.1 Penetration And Growth Prospect Mapping
3.2 Product Pipeline Analysis
3.3 Regulatory Framework
3.3.1 North America
3.3.2 Europe
3.3.3 Asia Pacific
3.3.4 Latin America
3.3.5 Middle East & Africa
3.4 Market Driver Analysis
3.4.1 Rising Incidence Of Meningitis
3.4.2 Rising R&D In Meningococcal Vaccines
3.4.3 Increasing Immunization Programs And Government Initiatives
3.4.4 Growing Support By Healthcare Services In Providing Low-Cost Meningococcal Vaccine
3.5 Market Restraint Analysis
3.5.1 High Cost Associated With Storage And Supply Of Vaccines
3.5.2 Challenges Associated With Vaccine Development
3.6 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
3.7 Porter’s Five Forces Analysis
3.8 Major Deals And Strategic Alliances Analysis
3.8.1 New Product Launches
3.8.2 Mergers And Acquisitions
3.8.3 Expansion
3.8.4 Partnerships
3.8.5 Marketing And Promotions
3.8.6 Market Entry Strategies
Chapter 4 Meningococcal Vaccines Market: Segment Analysis, By Type, 2021 - 2034 (USD Million)
4.1 Definition And Scope
4.2 Type Market Share Analysis, 2024 & 2034
4.3 Segment Dashboard
4.4 Global Meningococcal Vaccines Market, By Type, 2021 To 2034
4.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
4.5.1 Bivalent
4.5.1.1 Bivalent Market Estimates And Forecast, 2021 - 2034 (USD Million)
4.5.2 Quadrivalent
4.5.2.1 Quadrivalent Market Estimates And Forecast, 2021 - 2034 (USD Million)
4.5.3 Others
4.5.3.1 Others Market Estimates And Forecast, 2021 - 2034 (USD Million)
Chapter 5 Meningococcal Vaccines Market: Segment Analysis, By Brand, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.1 Definition And Scope
5.2 Brand Market Share Analysis, 2024 & 2034
5.3 Segment Dashboard
5.4 Global Meningococcal Vaccines Market, By Brand, 2021 To 2034
5.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
5.5.1 Menactra
5.5.1.1 Menactra Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.5.2 Menveo
5.5.2.1 Menveo Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.5.3 Nimenrix
5.5.3.1 Nimenrix Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.5.4 Trumenba
5.5.4.1 Trumenba Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.5.5 Bexsero
5.5.5.1 Bexsero Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
5.5.6 Others
5.5.6.1 Others Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
Chapter 6 Meningococcal Vaccines Market: Segment Analysis, By Age Group, 2021 - 2034 (USD Million)
6.1 Definition And Scope
6.2 Age Group Market Share Analysis, 2024 & 2034
6.3 Segment Dashboard
6.4 Global Meningococcal Vaccines Market, By Age Group, 2021 To 2034
6.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
6.5.1 Infants (0-2 Years)
6.5.1.1 Infants Market Estimates And Forecast, 2021 - 2034 (USD Million)
6.5.2 Children And Adults (2 Years And Above)
6.5.2.1 Children And Adults Market Estimates And Forecast, 2021 - 2034 (USD Million)
Chapter 7 Meningococcal Vaccines Market: Segment Analysis, By Serotype, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
7.1 Definition And Scope
7.2 Serotype Market Share Analysis, 2024 & 2034
7.3 Segment Dashboard
7.4 Global Meningococcal Vaccines Market, By Serotype, 2021 To 2034
7.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
7.5.1 Serotype A
7.5.1.1 Serotype A Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
7.5.2 Serotype B
7.5.2.1 Serotype B Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
7.5.3 Serotype C
7.5.3.1 Serotype C Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
7.5.4 Serotype W-135
7.5.4.1 Serotype W Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
7.5.5 Serotype Y
7.5.5.1 Serotype Y Market Estimates And Forecast, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
Chapter 8 Meningococcal Vaccines Market: Segment Analysis, By Sales Channel, 2021 - 2034 (USD Million)
8.1 Definition And Scope
8.2 Sales Channel Market Share Analysis, 2024 & 2034
8.3 Segment Dashboard
8.4 Global Meningococcal Vaccines Market, By Sales Channel, 2021 To 2034
8.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
8.5.1 Private
8.5.1.1 Private Market Estimates And Forecast, 2021 - 2034 (USD Million)
8.5.2 Public
8.5.2.1 Public Market Estimates And Forecast, 2021 - 2034 (USD Million)
Chapter 9 Meningococcal Vaccines Market: Segment Analysis, By Region, 2021 - 2034 (USD Million)
9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2024 & 2034
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 Market Size & Forecasts And Trend Analyses, 2021 To 2034
9.5.1 North America
9.5.1.1 North America Market Estimates And Forecasts, 2021 - 2034 (USD Million)
9.5.1.2 U.S.
9.5.1.2.1 Key Country Dynamics
9.5.1.2.2 Competitive Scenario
9.5.1.2.3 Regulatory Framework
9.5.1.2.4 Reimbursement Scenario
9.5.1.2.5 U.S. Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.1.3 Canada
9.5.1.3.1 Key Country Dynamics
9.5.1.3.2 Competitive Scenario
9.5.1.3.3 Regulatory Framework
9.5.1.3.4 Reimbursement Scenario
9.5.1.3.5 Canada Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2 Europe
9.5.2.1 Europe Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.2 Germany
9.5.2.2.1 Key Country Dynamics
9.5.2.2.2 Competitive Scenario
9.5.2.2.3 Regulatory Framework
9.5.2.2.4 Reimbursement Scenario
9.5.2.2.5 Germany Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.3 Uk
9.5.2.3.1 Key Country Dynamics
9.5.2.3.2 Competitive Scenario
9.5.2.3.3 Regulatory Framework
9.5.2.3.4 Reimbursement Scenario
9.5.2.3.5 Uk Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.4 France
9.5.2.4.1 Key Country Dynamics
9.5.2.4.2 Competitive Scenario
9.5.2.4.3 Regulatory Framework
9.5.2.4.4 Reimbursement Scenario
9.5.2.4.5 France Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.5 Spain
9.5.2.5.1 Key Country Dynamics
9.5.2.5.2 Competitive Scenario
9.5.2.5.3 Regulatory Framework
9.5.2.5.4 Reimbursement Scenario
9.5.2.5.5 Spain Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.6 Italy
9.5.2.6.1 Key Country Dynamics
9.5.2.6.2 Competitive Scenario
9.5.2.6.3 Regulatory Framework
9.5.2.6.4 Reimbursement Scenario
9.5.2.6.5 Italy Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.7 Russia
9.5.2.7.1 Key Country Dynamics
9.5.2.7.2 Competitive Scenario
9.5.2.7.3 Regulatory Framework
9.5.2.7.4 Reimbursement Scenario
9.5.2.7.5 Russia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.8 Belarus
9.5.2.8.1 Key Country Dynamics
9.5.2.8.2 Competitive Scenario
9.5.2.8.3 Regulatory Framework
9.5.2.8.4 Reimbursement Scenario
9.5.2.8.5 Belarus Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.9 Georgia
9.5.2.9.1 Key Country Dynamics
9.5.2.9.2 Competitive Scenario
9.5.2.9.3 Regulatory Framework
9.5.2.9.4 Reimbursement Scenario
9.5.2.9.5 Georgia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.10 Moldova
9.5.2.10.1 Key Country Dynamics
9.5.2.10.2 Competitive Scenario
9.5.2.10.3 Regulatory Framework
9.5.2.10.4 Reimbursement Scenario
9.5.2.10.5 Moldova Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.11 Denmark
9.5.2.11.1 Key Country Dynamics
9.5.2.11.2 Competitive Scenario
9.5.2.11.3 Regulatory Framework
9.5.2.11.4 Reimbursement Scenario
9.5.2.11.5 Denmark Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.12 Sweden
9.5.2.12.1 Key Country Dynamics
9.5.2.12.2 Competitive Scenario
9.5.2.12.3 Regulatory Framework
9.5.2.12.4 Reimbursement Scenario
9.5.2.12.5 Sweden Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.2.13 Norway
9.5.2.13.1 Key Country Dynamics
9.5.2.13.2 Competitive Scenario
9.5.2.13.3 Regulatory Framework
9.5.2.13.4 Reimbursement Scenario
9.5.2.13.5 Norway Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3 Asia Pacific
9.5.3.1 Asia Pacific Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.2 Japan
9.5.3.2.1 Key Country Dynamics
9.5.3.2.2 Competitive Scenario
9.5.3.2.3 Regulatory Framework
9.5.3.2.4 Reimbursement Scenario
9.5.3.2.5 Japan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.3 China
9.5.3.3.1 Key Country Dynamics
9.5.3.3.2 Competitive Scenario
9.5.3.3.3 Regulatory Framework
9.5.3.3.4 Reimbursement Scenario
9.5.3.3.5 China Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.4 India
9.5.3.4.1 Key Country Dynamics
9.5.3.4.2 Competitive Scenario
9.5.3.4.3 Regulatory Framework
9.5.3.4.4 Reimbursement Scenario
9.5.3.4.5 India Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.5 South Korea
9.5.3.5.1 Key Country Dynamics
9.5.3.5.2 Competitive Scenario
9.5.3.5.3 Regulatory Framework
9.5.3.5.4 Reimbursement Scenario
9.5.3.5.5 South Korea Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.6 Australia
9.5.3.6.1 Key Country Dynamics
9.5.3.6.2 Competitive Scenario
9.5.3.6.3 Regulatory Framework
9.5.3.6.4 Reimbursement Scenario
9.5.3.6.5 Australia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.7 Singapore
9.5.3.7.1 Key Country Dynamics
9.5.3.7.2 Competitive Scenario
9.5.3.7.3 Regulatory Framework
9.5.3.7.4 Reimbursement Scenario
9.5.3.7.5 Singapore Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.8 Thailand
9.5.3.8.1 Key Country Dynamics
9.5.3.8.2 Competitive Scenario
9.5.3.8.3 Regulatory Framework
9.5.3.8.4 Reimbursement Scenario
9.5.3.8.5 Thailand Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.9 Vietnam
9.5.3.9.1 Key Country Dynamics
9.5.3.9.2 Competitive Scenario
9.5.3.9.3 Regulatory Framework
9.5.3.9.4 Reimbursement Scenario
9.5.3.9.5 Vietnam Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.10 Malaysia
9.5.3.10.1 Key Country Dynamics
9.5.3.10.2 Competitive Scenario
9.5.3.10.3 Regulatory Framework
9.5.3.10.4 Reimbursement Scenario
9.5.3.10.5 Malaysia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.11 Indonesia
9.5.3.11.1 Key Country Dynamics
9.5.3.11.2 Competitive Scenario
9.5.3.11.3 Regulatory Framework
9.5.3.11.4 Reimbursement Scenario
9.5.3.11.5 Indonesia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.12 Kazakhstan
9.5.3.12.1 Key Country Dynamics
9.5.3.12.2 Competitive Scenario
9.5.3.12.3 Regulatory Framework
9.5.3.12.4 Reimbursement Scenario
9.5.3.12.5 Kazakhstan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.13 Kyrgyzstan
9.5.3.13.1 Key Country Dynamics
9.5.3.13.2 Competitive Scenario
9.5.3.13.3 Regulatory Framework
9.5.3.13.4 Reimbursement Scenario
9.5.3.13.5 Kyrgyzstan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.14 Armenia
9.5.3.14.1 Key Country Dynamics
9.5.3.14.2 Competitive Scenario
9.5.3.14.3 Regulatory Framework
9.5.3.14.4 Reimbursement Scenario
9.5.3.14.5 Armenia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.15 Azerbaijan
9.5.3.15.1 Key Country Dynamics
9.5.3.15.2 Competitive Scenario
9.5.3.15.3 Regulatory Framework
9.5.3.15.4 Reimbursement Scenario
9.5.3.15.5 Azerbaijan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.16 Tajikistan
9.5.3.16.1 Key Country Dynamics
9.5.3.16.2 Competitive Scenario
9.5.3.16.3 Regulatory Framework
9.5.3.16.4 Reimbursement Scenario
9.5.3.16.5 Tajikistan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.17 Turkmenistan
9.5.3.17.1 Key Country Dynamics
9.5.3.17.2 Competitive Scenario
9.5.3.17.3 Regulatory Framework
9.5.3.17.4 Reimbursement Scenario
9.5.3.17.5 Turkmenistan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.3.18 Uzbekistan
9.5.3.18.1 Key Country Dynamics
9.5.3.18.2 Competitive Scenario
9.5.3.18.3 Regulatory Framework
9.5.3.18.4 Reimbursement Scenario
9.5.3.18.5 Uzbekistan Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4 Latin America
9.5.4.1 Latin America Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.2 Brazil
9.5.4.2.1 Key Country Dynamics
9.5.4.2.2 Competitive Scenario
9.5.4.2.3 Regulatory Framework
9.5.4.2.4 Reimbursement Scenario
9.5.4.2.5 Brazil Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.3 Mexico
9.5.4.3.1 Key Country Dynamics
9.5.4.3.2 Competitive Scenario
9.5.4.3.3 Regulatory Framework
9.5.4.3.4 Reimbursement Scenario
9.5.4.3.5 Mexico Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.4 Argentina
9.5.4.4.1 Key Country Dynamics
9.5.4.4.2 Competitive Scenario
9.5.4.4.3 Regulatory Framework
9.5.4.4.4 Reimbursement Scenario
9.5.4.4.5 Argentina Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.5 Chile
9.5.4.5.1 Key Country Dynamics
9.5.4.5.2 Competitive Scenario
9.5.4.5.3 Regulatory Framework
9.5.4.5.4 Reimbursement Scenario
9.5.4.5.5 Chile Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.6 Cuba
9.5.4.6.1 Key Country Dynamics
9.5.4.6.2 Competitive Scenario
9.5.4.6.3 Regulatory Framework
9.5.4.6.4 Reimbursement Scenario
9.5.4.6.5 Cuba Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.7 Ecuador
9.5.4.7.1 Key Country Dynamics
9.5.4.7.2 Competitive Scenario
9.5.4.7.3 Regulatory Framework
9.5.4.7.4 Reimbursement Scenario
9.5.4.7.5 Ecuador Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.8 Peru
9.5.4.8.1 Key Country Dynamics
9.5.4.8.2 Competitive Scenario
9.5.4.8.3 Regulatory Framework
9.5.4.8.4 Reimbursement Scenario
9.5.4.8.5 Peru Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.9 Colombia
9.5.4.9.1 Key Country Dynamics
9.5.4.9.2 Competitive Scenario
9.5.4.9.3 Regulatory Framework
9.5.4.9.4 Reimbursement Scenario
9.5.4.9.5 Colombia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.4.10 Venezuela
9.5.4.10.1 Key Country Dynamics
9.5.4.10.2 Competitive Scenario
9.5.4.10.3 Regulatory Framework
9.5.4.10.4 Reimbursement Scenario
9.5.4.10.5 Venezuela Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5 Middle East & Africa
9.5.5.1 Middle-East And Africa Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.2 South Africa
9.5.5.2.1 Key Country Dynamics
9.5.5.2.2 Competitive Scenario
9.5.5.2.3 Regulatory Framework
9.5.5.2.4 Reimbursement Scenario
9.5.5.2.5 South Africa Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.3 Saudi Arabia
9.5.5.3.1 Key Country Dynamics
9.5.5.3.2 Competitive Scenario
9.5.5.3.3 Regulatory Framework
9.5.5.3.4 Reimbursement Scenario
9.5.5.3.5 Saudi Arabia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.4 Uae
9.5.5.4.1 Key Country Dynamics
9.5.5.4.2 Competitive Scenario
9.5.5.4.3 Regulatory Framework
9.5.5.4.4 Reimbursement Scenario
9.5.5.4.5 Uae Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.5 Algeria
9.5.5.5.1 Key Country Dynamics
9.5.5.5.2 Competitive Scenario
9.5.5.5.3 Regulatory Framework
9.5.5.5.4 Reimbursement Scenario
9.5.5.5.5 Algeria Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.6 Egypt
9.5.5.6.1 Key Country Dynamics
9.5.5.6.2 Competitive Scenario
9.5.5.6.3 Regulatory Framework
9.5.5.6.4 Reimbursement Scenario
9.5.5.6.5 Egypt Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.7 Tunisia
9.5.5.7.1 Key Country Dynamics
9.5.5.7.2 Competitive Scenario
9.5.5.7.3 Regulatory Framework
9.5.5.7.4 Reimbursement Scenario
9.5.5.7.5 Tunisia Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.8 Iran
9.5.5.8.1 Key Country Dynamics
9.5.5.8.2 Competitive Scenario
9.5.5.8.3 Regulatory Framework
9.5.5.8.4 Reimbursement Scenario
9.5.5.8.5 Iran Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.9 Turkey
9.5.5.9.1 Key Country Dynamics
9.5.5.9.2 Competitive Scenario
9.5.5.9.3 Regulatory Framework
9.5.5.9.4 Reimbursement Scenario
9.5.5.9.5 Turkey Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.10 Iraq
9.5.5.10.1 Key Country Dynamics
9.5.5.10.2 Competitive Scenario
9.5.5.10.3 Regulatory Framework
9.5.5.10.4 Reimbursement Scenario
9.5.5.10.5 Iraq Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.11 Morocco
9.5.5.11.1 Key Country Dynamics
9.5.5.11.2 Competitive Scenario
9.5.5.11.3 Regulatory Framework
9.5.5.11.4 Reimbursement Scenario
9.5.5.11.5 Morocco Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
9.5.5.12 Kuwait
9.5.5.12.1 Key Country Dynamics
9.5.5.12.2 Competitive Scenario
9.5.5.12.3 Regulatory Framework
9.5.5.12.4 Reimbursement Scenario
9.5.5.12.5 Kuwait Market Estimate And Forecasts, 2021 - 2034 (USD Million) (Volume, Number Of Doses (In Thousands))
Chapter 10 Competitive Landscape
10.1 Company Categorization
10.2 Strategy Mapping
10.2.1 New Product Launch
10.2.2 Partnerships
10.2.3 Acquisition
10.2.4 Collaboration
10.2.5 Funding
10.3 Key Company Market Share Analysis, 2022
10.4 Company Profiles
10.4.1 Sanofi
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 Merck & Co., Inc.
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.2.4 Strategic Initiatives
10.4.3 Gsk Plc
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 Serum Institute Of India Pvt. Ltd.
10.4.4.1 Company Overview
10.4.4.2 Product Benchmarking
10.4.4.3 Strategic Initiatives
10.4.5 Pfizer, Inc.
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 Walwax Biotechnology Co., Ltd
10.4.6.1 Company Overview
10.4.6.2 Product Benchmarking
10.4.6.3 Strategic Initiatives
10.4.7 Petrovax
10.4.7.1 Company Overview
10.4.7.2 Product Benchmarking
10.4.7.3 Strategic Initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers